Skip to Content

Pharma & Biotech Logistics in Switzerland: Qualification Checklist

November 17, 2026 by
Pharma & Biotech Logistics in Switzerland: Qualification Checklist
Lazhar Cader

Prerequisites before qualifying the flow

How to connect the pickup from a European supplier, the customs formalities, the reception in the warehouse, the order preparation and the delivery in Switzerland without losing traceability or transferring the quality decisions to the logistics provider?

The scenario followed is fictional. A European biotech company ships temperature-sensitive products to a Swiss warehouse, then to laboratories and health clients. It serves to examine the interfaces, without presuming the product, volume, temperature, or site. In 2025, more than 80% of Swiss imports of chemical and pharmaceutical products come from the EU.

 

Before starting, gather :

  • the product specifications and handling instructions ;
  • the stability data provided by the manufacturer ;
  • the diagram of the physical and documentary flow ;
  • the contractual responsibilities ;
  • the contacts and escalation timelines ;
  • the rules for quarantine, acceptance, release and rejection.

 

Separate finished pharmaceutical products, biotech materials and laboratory samples. For each category, define the regulatory status, batch or sample identifier, thermal sensitivity, required documents, and the decision authority. The same procedure may not necessarily apply to all three categories.

Note that since July 1, 2026, certain medical devices and diagnostic tests must be registered in swissdamed, with a deadline until December 31 2026. Before organizing their transport, check if your products are affected and who must register them.

For medicines, import, export, and wholesale activities must comply with good distribution practices (GDP). The company must have a responsible person and a suitable documentation system, according to the applicable activities and permissions (Fedlex) [1]. The documented qualification of partners and the traceability of the chain must follow the technical interpretation of Swissmedic [2].

◉ Actor

▣ Role

▤ Data

☐ Control

✓ Validation

◉ Manufacturer

▣ Define storage criteria

▤ Specifications, stability, product identification

☐ Before qualification and shipping

✓ Approves product requirements

◉ Quality team

▣ Evaluate deviations and manage quality status

▤ Release rules, deviations, decisions

☐ Before shipping, upon receipt, and during a deviation

✓ Releases, quarantines or rejects according to its authorization

◉ Customs representative

▣ Prepare or transmit the agreed formalities

▤ Declaration, proposed classification, import data

☐ Before deposit and at customs clearance

✓ Accepts the file for processing, without deciding on quality status

◉ Warehouse

▣ Receive, store, prepare and trace

▤ Receiving register, WMS, stock statuses

☐ Receiving, storing and preparing

✓ Accepts the operation according to the instructions

◉ Carrier

▣ Remove, transport, deliver and report incidents

▤ Transport document, tracking, reservations

☐ Removal, transfers and delivery

✓ Accepts the physical takeover

◉ Swiss recipient

▣ Control the delivery and formulate reservations

▤ Proof of delivery, receipt confirmation

☐ Final delivery

✓ Accepts the delivery or issues a reservation

The release authority remains that defined by the manufacturer or the authorized quality team. The warehouse and the carrier execute, record and report the operations. They do not independently release the product.

Qualification and implementation steps

1. Classify the product and formalize its handling requirements


Create a qualification sheet for each category. Indicate the product status, tracked identifiers, the manufacturer's storage conditions, the intended packaging, and the allowable transit time. Add the security level, monitoring mode, and the quality manager responsible for decisions.

Finished products, biotech materials, and samples may follow distinct traceability and acceptance rules. For example, a sample identifier should not be replaced by a commercial reference if this substitution breaks the audit trail. For samples containing pathogens, check their risk level before shipping. In Switzerland, the importation of human pathogens from groups 3 and 4 must be reported to the Federal Office of Public Health (FOPH).

 

  • Responsible: manufacturer, product owner, and quality team.
  • Required document or data: approved qualification sheet, specifications, stability data, and decision rules.
  • Control: compare the requirements of the sheet with the labeling, shipping documents, and intended capabilities.
  • Acceptance criterion: each category has consistent, approved, and usable instructions for operators (refer to the official database SwissGMDP)

 

Advice: use the exact terms used in the specifications. Avoid converting a storage condition into a generic range. According to the guidelines from Swissmedic updated in December 2025, medications must be transported and stored under the conditions specified by the manufacturer. These conditions must be documented and monitored throughout the journey. The company must also verify that the carrier can comply with them.

Expected result : teams know which data to track and who can accept a deviation.

Note that since July 2026, Swissmedic charges 200 CHF for the first UDI-DI identifier registered in swissdamed and 20 CHF per additional identifier having the status of “on the market,” with an annual cap of 10,000 CHF. The first invoices are expected in January 2027.

 


2. Map the European-Swiss journey and interfaces


Establish the following textual mapping :

European supplier → pickup → exit EU → border crossing and Swiss customs clearance → warehouse receipt → preparation → delivery to the laboratory or healthcare client → proof of delivery

For each arrow, name the physical holder of the package, the data holder, and the escalation contact. Specify when the operational responsibility changes and the system that records this change.

Also document waiting periods, as a vehicle held up or goods detained in customs remain subject to the product's instructions.  Since 2026, Switzerland is gradually replacing its e-dec Import customs system with Passar. The 2 systems will continue to be used until September 30, 2027. Ask your freight forwarder which one they use and how they transmit and store the customs documents.

Identify the actor who consults the thermal data and the one who receives an alert.

 

  • Responsible: supply chain responsible, with the quality, customs, warehouse, and transport teams.
  • Required document or data: flow mapping, escalation directory, and list of systems.
  • Control: check that no physical or documentary transfer remains without an owner.
  • Acceptance criteria: each interface indicates an owner, a record, and an alert circuit.

 

Example to record: indicate separately who holds the package at the dock and who validates its status in the WMS.

 


3. Distribute the regulatory obligations and quality decisions


Check the applicable authorizations for the product and each activity. Define the BPD scope, the responsibilities of the importer, the responsibility for tariff classification, and the access rights to the data.

According to the guidelines from Swissmedic updated in September 2026, a pharmaceutical company may entrust the receipt, storage, and delivery of its medications to an authorized provider. However, it remains responsible for the release of the batches and must specify the role of each in a quality agreement.

Explicitly assign the powers to accept, quarantine, release, or reject. A correct physical receipt does not constitute quality release. The decision must be assigned to an authorized function and remain traceable.

Swissmedic requires documented evidence that suppliers and customers are authorized to conduct their relevant activities and comply with applicable standards. This verification is part of the qualification of partners and should not be limited to a contractual declaration.

 

  • Responsible: quality team, importer and regulatory responsible.
  • Required document or data: applicable licenses, activity scopes, quality agreement and decision matrix.
  • Control: match each actual activity with the corresponding authorization, contract, and procedure (consult SwissGMDP to verify its authorizations.
  • Acceptance criterion: regulatory responsibilities and quality decisions are assigned unambiguously.

 

Warning: confirm the status according to the product and activity. The requirements are not the same for all biotech or medical flows.

 


4. Prepare the customs file and shipping instructions


Before pickup, align the commercial invoice, the precise description, origin, value, and quantity. Also check the proposed tariff classification, Incoterm, transport document, the recipient, import status, and temperature instructions.

Customs declarations, tariff classification, as well as duties or taxes fall under Swiss customs law. The therapeutic status may also entail separate authorization obligations (IBA inquiry on Switzerland) [3].


  • Responsible: exporter, importer and customs representative according to the contractual distribution.
  • Required document or data: file presented in the table below.
  • Control: perform a documentary reconciliation before the removal authorization.
  • Acceptance criterion: the descriptions, quantities, identities and instructions match.

▤ Document

◉ Responsible

◷ 
Control

▣ Traceability

✓ Validation

▤ Commercial invoice

◉ Exporter

◷ Before removal

▣ Product, quantity, origin, value

✓ Match with the goods

▤ Shipping instructions

◉ Order giver

◷ Before removal

▣ Batch or sample, handling

✓ Approved and applicable version

▤ Transport document

◉ Carrier / freight forwarder

◷ At pickup

▣ Shipper, recipient, package

✓ Match with the shipment

▤ Customs declaration

◉ Designated declarant

◷ Before submission and customs

▣ Classification, origin, value, status

✓ Complete and consistent data

▤ Thermal record

◉ Carrier or designated system

◷ During the journey and upon receipt

▣ Device identifier and shipment

✓ Recoverable and usable data

▤ Receipt register

◉ Warehouse

◷ Upon arrival

▣ Date, quantity, batch, supplier

✓ Reconciliation completed

▤ Stock status

◉ Warehouse in the WMS

◷ After receipt and at each movement

▣ Location, batch, quality status

✓ Status compliant with instruction

▤ Proof of delivery

◉ Carrier and recipient

◷ At the final handover

▣ Shipping, time, remarks

✓ Handover identifiable and documented

▤ Deviation report

◉ Designated function

◷ Upon detection of a deviation

▣ Product, event, evidence

✓ Deviation recorded and transmitted

Expected result : the file can circulate between export, customs, transport, and receipt without contradictory re-entry.



5. Qualify the packaging, thermal monitoring, and transport conditions


Document the adequacy of the packaging, vehicle, or container for the journey. Define the position of the tracking device, alert thresholds, alerted contacts, and response times.

Add the loading, waiting, and transfer conditions. The applicable temperature derives from the manufacturer's instructions and the qualification of the journey. It should not come from a range used by default.

The conditions of each incoming and outgoing delivery must remain appropriate throughout the chain. The corresponding evidence must be accessible for quality assessment.

 

  • Responsible : manufacturer or quality team for requirements, logistics provider for qualified execution.
  • Required document or data: route qualification, packaging configuration, associated device and alert procedure.
  • Control: check the packaging before departure, the device identifier, its positioning and the contacts.
  • Acceptance criteria: the configuration matches the product, the route and the foreseeable transfer conditions.

 

Before entrusting your products to a carrier, request the results of tests conducted on the packaging and the planned routes. Also check how temperature deviations are recorded, reported and handled. In case of deviation, the quality team must be able to consult the data before deciding whether the products can be used or delivered.

The search for cold chain logistics for pharmaceutical companies in Switzerland or temperature-controlled transport of biotechnology products to Switzerland must therefore lead to examining the proof of the actual route, not a generally declared capacity.

 


6. Organize the warehouse reception, stock control and traceability


Upon arrival, check the external integrity before opening or moving. Bring together the packages and documents, verify the quantities and read the available identifiers. Then retrieve the thermal data.

Record the reception time, location and status of the stock. Isolate any difference from the available stock until a documented decision is made. This rule covers damages, inconsistent identifiers, missing data and quantitative discrepancies.

The expected transactional records include notably the date, quantity, lot number, expiration date, the precise description, and the identity with the address of the supplier and the customer (technical interpretation by Swissmedic) [4].

Before choosing a warehouse, ensure that its WMS can track lot numbers, expiration dates, and the status of each product. A lot in quarantine must be blocked in the system to prevent any preparation or delivery before the quality team's agreement. Read the Certificates of Good Manufacturing Practices from Swiss GMDP for more information.

 

  • Responsible: receiving team and warehouse manager.
  • Required document or data: shipping document, thermal data, receiving log, and WMS.
  • Control: compare packages, quantities, identifiers, apparent condition, and document status.
  • Acceptance criteria: each received unit has a controlled status and an audit trail.

 

This discipline also applies to the storage and distribution of medical devices in Switzerland when the device status and the manufacturer's instructions require it.

 


7. Define the order preparation, release, and final delivery


Define the order trigger and the pre-check of stock status. Organize picking, final inspection, shipping packaging, handover to the carrier, and collection of the delivery proof.

The release instruction must be identifiable. The provider executes the recorded decision and does not replace the quality team. Set up a block preventing the preparation of a unit in quarantine, if the system allows it.

A warehouse management system, or WMS, can support the inventory control and record the movements. STAR Logistique uses advanced technology and a WMS for the inventory control.

 

  • Responsible: order giver, quality authority, warehouse and carrier for their respective operations.
  • Required document or data: order, WMS status, release instruction and proof of delivery.
  • Control: match product, batch or sample, quantity, recipient and status before handover.
  • Acceptance criteria: only authorized items leave the warehouse, with traceability to the recipient.


To evaluate 3PL providers in the pharmaceutical sector in Switzerland or logistics service providers in the healthcare sector in Switzerland, check this separation of roles in the procedures and systems.

 


8. Control each transfer between transport, customs and warehouse


Record the chain of custody at each pickup, customs clearance, receiving dock, intersite transfer, handover to the carrier and delivery. Each record must link the event to the concerned shipment.

Record the timestamp, the identity of the intervenor, the apparent condition, the customs status, the available thermal data, the reserves and the acceptance of the recipient. Define who completes the record and who verifies its consistency.

The joint preparation of customs documents and temperature instructions reduces breaks between the administrative flow and the physical flow. Use the STAR Logistique guide on pharmaceutical transport and customs formalities as a checklist before departure.

 

  • Responsible: physical holder at each transfer, under the control of the flow manager.
  • Required document or data: chain of custody record and associated documentation.
  • Control: check the chronological continuity and the recorded signatures or identities.
  • Acceptance criterion: no change of custody remains without proof or status.

 

Expected outcome: an investigation can reconstruct the path without relying on the memories of the intervenors.

 


9. Address temperature deviations, delays, damages, and returns


Apply the following decision flow to each incident:

Detection → securing → recording → notification → quality assessment → documented decision → restocking, release, return or rejection

Place the affected units in quarantine when the applicable procedures require it, until the documented decision of the authorized quality team.

 

  • Thermal excursion: keep the raw data, secure the products and forward the file to the quality team.
  • Delay : document its duration, the conditions of waiting and its possible effect on the qualified route.
  • Visible damage : photograph or describe the condition, issue reservations and isolate the affected units.
  • Quantitative deviation : reconcile the receipt, the invoice, the transport document and the identifiers.
  • Return : place the product under the intended status before any restocking assessment.

 

In the fictional scenario, a deviation is detected during the transport and the quantity received differs from the documents. Both deviations open a deviation and require a documented decision, without automatic release.

 

  • Responsible : first detector for the reporting, quality team authorized for the decision.
  • Required document or data : raw data, timeline, evidence, deviation report.
  • Control : confirm the securing, the notification and the preservation of the elements.
  • Acceptance criterion : each deviation leads to a justified and traceable decision.

 


10. Measure the performance, investigate the deviations and improve the flow


Build a dashboard with the rate of thermal deviations, the rate of documentary errors, inventory accuracy and the time between release and shipment. Add the rate of complete and on-time deliveries as well as the closure time for deviations.

Do not impose a generic threshold. Agree on objectives in the quality and service agreements, according to the product and the risk. For each indicator, assign an owner, a review frequency, a data source, and a possible corrective action.

 

  • Responsible: supply chain manager with the quality, customs, warehouse, and transport owners.
  • Required document or data: definitions of the indicators, system exports, reports, and action plan.
  • Control: check the quality of the data and analyze the causes, not just the total number of incidents.
  • Acceptance criteria: each indicator is reproducible, assigned, and linked to a decision.

 

An increase in document errors may lead to modifying a model or control before removal. A repeated deviation at an interface may justify a new qualification of the transfer.

Expected result: management transforms the flow events into actions followed until their closure.

Management tips and best practices

Conduct a review before commissioning. Involve the people who carry out the removal, reception, preparation, and deliveries. They must confirm that the instructions are understandable and applicable in real conditions.

Test the document interfaces with a representative file. Check the mandatory fields, identifiers, schedules, document versions, and the transmission of documents. Then simulate an incident, such as an out-of-hours thermal alert or an inconsistent customs document.

 

Record the interfaces between the integrated management software (ERP), the WMS, the thermal tracking system, and the customs data. Define:

  • the transmitted data and their reference system;
  • the rights of reading, modification, and export;
  • the format of the exports provided during an investigation;
  • the contractual retention period;
  • the procedure applied in case of unavailability of a system.

 

Ensure that the stakeholders are aware of the emergency procedures, contact windows, and the decision-making circuit outside of business hours. An escalation number is not enough if no one knows what evidence to provide.

The STAR Logistique guide on pharmaceutical cold chain logistics helps to deepen prior definition of the product, the route, thermal data, and responsibilities.

After commissioning, hold a periodic review of discrepancies and indicators. Compare the procedures to the observed execution. A solid qualification relies on available evidence, mastery of interfaces, and the reality of the flow, rather than just on the announced capabilities.

Frequent errors and corrective actions

Assess the level of risk according to the product, the status of the flow, and the applicable procedures. An operational error does not automatically constitute a regulatory non-compliance, but it requires a documented analysis.

 

  • Imprecise product designation → uncertain customs classification, delayed control, or document inconsistency → use the approved description and compare it with the invoice, authorizations, and the physical product.
  • Release assigned to the carrier or the warehouse → decision made outside the authorized authority → block the status until identifiable instruction from the authorized quality team.
  • Transport initiated without thermal acceptance criteria → data collected without evaluation rule → define before departure the manufacturer's conditions, monitoring, and decision-making process.
  • Owner of the customs declaration not identified → contradictory information or lack of correction → assign preparation, validation, and transmission to named functions.
  • Quantities close together without considering lots or samples → misleading overall match → compare each identifier with physical receipt, invoice, transport document, and shipping instruction.
  • Thermal alert treated as mere information → product used before evaluation → retain the raw data, check the circumstances, and forward the file to the quality team.
  • Return placed directly into available stock → previous status assumed without proof → place the return in quarantine or under the expected status until a documented decision.
  • Proof of delivery separate from lots and quality status → inability to demonstrate what has been delivered → link the proof to the shipment, tracked identifiers, and the applicable decision.

 

In the quantitative deviation scenario, compare the physical receipt, the commercial invoice, the transport document, the shipping instruction, and the lot or sample identifiers. Place the concerned unit under the expected status until the documented decision.

For the thermal excursion, preserve the raw file and the device metadata. Reconstruct the loading, expectations, transfers, and the route. The quality team then evaluates the event against the applicable specifications. The logistics provider never releases the product alone.

The storage of medicines or innovative therapy products, or ATMP, under customs or in a customs warehouse may already be considered an import. This situation may require an import authorization and enhanced due diligence, depending on the activity and the product, as indicated by the technical interpretation of Swissmedic.

Expected results after qualification

At the end of the qualification, you have an approved flow file, a responsibility matrix, and consistent instructions for shipping and receiving. The systems and documents allow you to trace the chain of custody, stock status, and quality decisions.

 

Check the results with this final checklist:

☐ Finished products, biotech materials, and samples follow distinct categories.

☐ Quality, customs, and operational responsibilities are assigned.

☐ Invoices, instructions, transport documents, and customs data match.

☐ Temperature and chain of custody evidence remain retrievable.

☐ Each lot, item, or sample has a controlled stock status.

☐ Quarantine, release, return, or rejection decisions are documented.

☐ The deviation circuit protects the evidence and assigns the evaluation to the authorized authority.

☐ The indicators have an owner, a source, and a review frequency.

☐ Simulated incidents confirm that contacts and systems function in practice.

 

Operational acceptance is based on the criteria of the manufacturer, the competent quality authority, and applicable obligations. It cannot arise from a general promise of transport, storage, or tracking.

The next review should examine the initial execution data, the observed deviations, and the quality of the records. Then adjust the controls, responsibilities, or route qualification when the evidence shows a weakness.

Pharma & Biotech Logistics in Switzerland: Qualification Checklist
Lazhar Cader November 17, 2026
Share this post
Archive